在台湾接受了基于利多米德的治疗方案的复发/耐药多发性骨髓瘤 (RRMM) 患者中的治疗模式
Chieh-Lin Jerry Teng1,2,3, Su-Peng Yeh4, Tsai-Yun Chen5
1Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
Hematology (Amsterdam, Netherlands)
|July 3, 2024
概括
在台湾,针对复发性/耐药性多发性骨髓瘤 (RRMM) 的三重治疗方案显示出比双重治疗方案更好的结果. 然而,退款限制影响了三重治疗的持续时间,这表明改善患者护理的潜力.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药物经济学 药物经济学
背景情况:
- 复发性/耐药性多发性骨髓瘤 (RRMM) 治疗在台湾正在发展.
- 了解当前的治疗模式对于优化患者护理至关重要.
研究的目的:
- 评估台湾RRMM患者的治疗模式,这些患者接受了基于利多米德的疗法.
- 为了在RRMM中比较双重和三重治疗方案之间的结果.
主要方法:
- 对用波马利多米德治疗的RRMM患者 (≥20岁) 的回顾性,非干预性图表审查 (2020年1月至12月).
- 来自五个台湾医疗中心收集的数据.
- 分析治疗方案,初始剂量,改变治疗的原因和结果.
主要成果:
- 患者的中位年龄为65.6岁;75%接受了双重治疗方案,25%接受了三重治疗方案.
- 与双倍疗法相比,三倍疗法显示出更高的整体应答率 (45.8% vs 31.5%) 和更长的无进展生存时间 (6.8 vs 4.7 个月) 的中位数.
- 疾病的进展是转换到波马利多米德的首要原因;双剂断药主要是由于进展/死亡,而三剂断药受到补偿限制的影响.
结论:
- 基于波马利多米德的三倍疗法在台湾的RRMM患者中显示出更高的疗效趋势.
- 报销政策对三重疗法的使用和持续时间有重大影响.
- 三重疗法可能比RRMM的双重疗法更有效的治疗选择,因此需要进一步研究RRMM的获取和成本效益.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...